Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study

被引：46

作者：

Marshall, A. D. ^{[1
]}

Micallef, M. ^{[1
]}

Erratt, A. ^{[1
]}

Telenta, J. ^{[2
]}

Treloar, C. ^{[3
]}

Everingham, H. ^{[4
]}

Jones, S. C. ^{[2
]}

Bath, N. ^{[4
]}

How-Chow, D. ^{[5
]}

Byrne, J. ^{[6
]}

Harvey, P. ^{[7
]}

Dunlop, A. ^{[8
,9
]}

Jauncey, M. ^{[6
]}

Read, P. ^{[1
,10
]}

Collie, T. ^{[11
]}

Dore, G. J. ^{[1
]}

Grebely, J. ^{[1
]}

机构：

[1] UNSW Australia, Kirby Inst, Sydney, NSW, Australia

[2] Australian Catholic Univ, Ctr Hlth & Social Res, Sydney, NSW 2059, Australia

[3] UNSW Australia, Ctr Social Res Hlth, Sydney, NSW, Australia

[4] NSW Users & AIDS Assoc Inc, Sydney, NSW, Australia

[5] St Vincents Hosp, Sydney, NSW 2010, Australia

[6] Australian Injecting & Illicit Drug Users League, Canberra, ACT, Australia

[7] Hepatitis NSW, Sydney, NSW, Australia

[8] Univ Newcastle, Newcastle, NSW 2300, Australia

[9] Hunter New England Local Hlth Dist, Drug & Alcohol Clin Serv, Newcastle, NSW, Australia

[10] Kirketon Rd Ctr, Sydney, NSW, Australia

[11] Coffs Harbour Drug & Alcohol Serv, Sydney, NSW, Australia

来源：

INTERNATIONAL JOURNAL OF DRUG POLICY | 2015年 / 26卷 / 10期

基金：

澳大利亚研究理事会; 英国医学研究理事会;

关键词：

HCV; Drug users; Hepatitis C; PWID; Knowledge; Willingness; C VIRUS-INFECTION; INNER-CITY RESIDENTS; HEPATITIS-C; TRANSIENT ELASTOGRAPHY; SPECIALIST ASSESSMENT; USERS; BARRIERS; AUSTRALIA; ETHOS; FACILITATORS;

D O I：

10.1016/j.drugpo.2015.07.002

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Background: The aim of this study was to assess factors associated with baseline knowledge of HCV and liver disease, acceptability of transient elastography (TE) assessment (FibroScan (R)), and willingness and intent to receive HCV treatment among persons with a history of injection drug use participating in a liver health promotion campaign. Methods: The LiveRLife campaign involved three phases: (1) campaign resource development; (2) campaign resource testing; and (3) campaign implementation. Participants were enrolled in an observational cohort study with recruitment at four clinics - one primary health care facility, two OST clinics, and one medically supervised injecting centre - in Australia between May and October 2014. Participants received educational material, nurse clinical assessment, TE assessment, dried blood spot testing, and completed a knowledge survey. Results: Of 253 participants (mean age 43 years), 68% were male, 71% had injected in the past month, and 75% self-reported as HOT positive. Median knowledge score was 16/23. In adjusted analysis, less than daily injection (AOR 5.01; 95% CI, 2.64-9.51) and no daily injection in the past month (AOR 3.54; 95% CI, 1.80-6.94) were associated with high knowledge (>= 16). TE was the most preferred method both pre- (66%) and post-TE (89%) compared to liver biopsy and blood sample. Eighty-eight percent were 'definitely willing' or 'somewhat willing' to receive HCV treatment, and 56% intended to start treatment in the next 12 months. Approximately 68% had no/mild fibrosis (F0/F1, >= 2.5 to <= 7.4 kPa), 13% moderate fibrosis (F2, >= 7.5 to <= 9.4 kPa), 10% severe fibrosis (F3, >= 9.5 to <= 12.4 kPa), and 9% had cirrhosis (F4, >= 12.5 kPa). Conclusion: Liver disease and HCV knowledge was moderate. High acceptability of TE by PWID provides strong evidence for the inclusion of TE in HCV-related care, and could help to prioritise HCV treatment for those at greatest risk of liver disease progression. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：984 / 991

页数：8

共 33 条

[1] Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study [J].